Document is current

Article History

Received: 20 October 2022

Accepted: 23 January 2023

First Online: 31 January 2023

Declarations

:

: Access to CPRD data is subject to protocol approval by CPRD’s Research Data Governance (RDG) Process (former ISAC) (ExternalRef removed), Medicines and Healthcare Products Regulatory Agency, London, UK. The study protocol (Protocol No 19_132A2) was approved by CPRD’s RDG in July 2019, and can be made available to the journal reviewers upon request. No patient consent need to be collected for GP practices to share data with CPRD, as no information that can identify a patient is send to CPRD by the contributing practices (ExternalRef removed). The data accessed met the relevant data privacy and protection regulations and research was conducted according to the Declaration of Helsinki.

: Not applicable.

: DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants organized by his department outside the submitted work. Dr VS reports receiving grant support from NIHR Research for Patient Benefit (RfPB) and Amgen, and receiving advisory or speaker payment from Astellas Pharma. All other authors declared that they have no conflict of interest to be declared.